Granules India Q2 profit rises around 34 percent on strong revenue growth
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than Nifty Smallcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Granules India reported consolidated Q2 FY26 revenue of Rs 12,970 million, up about 34 percent year on year, with profit after tax rising to Rs 1,306 million from Rs 973 million. EPS rose to Rs 5.38 from Rs 4.01. Half year revenue grew to Rs 25,071 million and PAT to Rs 2,432 million. H1 exceptional items included Rs 121.60 million in Senn Chemicals AG acquisition costs, GPI litigation settlements, and a gain from disposal of an old investment. The Gagillapur facility remains under a USFDA warning letter, weighing on production. Auditors gave a clean limited review.
Strong revenue and profit growth driven by acquisitions and product mix, though USFDA warning letter at Gagillapur remains a key overhang for investors.